Treatment sequencing in metastatic castrate-resistant prostate cancer

Asian Journal of Andrology

Volumn 16, Issue 3, 2014, Pages 426-431

  Sartor, Oliver ^a   Gillessen, Silke ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medical Oncology Kantonsspital St Gallen ^*  (Switzerland)

Author keywords

Abiraterone; Cabazitaxel; Castrate resistant; Docetaxel; Enzalutamide; Radium 223; Sipuleucel T

Indexed keywords

ABIRATERONE; AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; DASATINIB; DOCETAXEL; ENZALUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; LENALIDOMIDE; MITOXANTRONE; PREDNISONE; RADIOISOTOPE; RADIUM 223; SIPULEUCEL T; STRONTIUM; UNCLASSIFIED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; RADIOPHARMACEUTICAL AGENT; RADIUM; RADIUM CHLORIDE RA 223; TAXOID; TISSUE EXTRACT;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CROSS RESISTANCE; HUMAN; METASTASIS; PROGRESSION FREE SURVIVAL; RADIUM THERAPY; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; CLINICAL TRIAL (TOPIC); MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY;

ANDROSTENOLS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM; TAXOIDS; TISSUE EXTRACTS;

EID: 84900507214     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.126378     Document Type: Review

References (28)

1. Tannock IF de Wit R Berry WR Horti J Pluzanska A et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
2. Petrylak DP Tangen CM Hussain MH Lara PN Jr Jones JA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
3. de Bono JS Oudard S Ozguroglu M Hansen S Machiels JP et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: Randomised open-label trial. Lancet 2010; 376: 1147-54
4. de Bono JS Logothetis CJ Molina A Fizazi K North S et al. Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 2011; 364: 1995-2005
5. Scher HI Fizazi K Saad F Taplin ME Sternberg CN et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng J Med 2012; 367: 1187-97
6. Kantoff PW Higano CS Shore ND Berger ER Small EJ et al. Sipuleucel-T immunotherapy for castration resistant prostate cancer. New Engl J Med 2010; 363: 411-22
7. Parker C Nilsson S Heinrich D Helle SI O'Sullivan JM et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-23
8. Ryan CJ Smith MR De Bono JS Molina A Logothetis CJ et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 2013; 368: 138-48
9. http://investors.medivation.com/releasedetail.cfm?.ReleaseID=798880 (accessed November 19 2013
10. Mezynski J Pezaro C Bianchini D Zivi A Sandhu S et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: Clinical evidence for cross-resistance?. Ann Oncol 2012; 23: 2943-7
11. Caffo O Burgio LS Di Lorenzo G Scognamiglio F Zustovichet F et al. Clinical outcomes (CO) evaluation of very old (=80 years) castration resistant prostate cancer (CRPC) patients (pts) treated with docetaxel (DOC): Updated results of an Italian multicenter retrospective study (cooperative group for DELPHI study). European Cancer Conference 2013 abstract 2908
12. Aggarwal RR Formaker C Small EJ Molina A Ryan CJ et al. Response to ketoconazole (keto) or docetaxel (D) following clinical progression on abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC). Clin Oncol 30 2012 (suppl; abstr 4664
13. Pezaro CJ Le Moulec S Albiges L Omlin AG Loriot Y et al. Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate. J Clin Oncol 31 2013 (suppl 6; abstr 155
14. Wissing MD Coenen JLLM Van Den Berg P Van Oort IM De Wit R et al. A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in Docetaxel treated metastatic castrate-resistant prostate cancer patients. Eur Cancer Congr 2013 abstract 2904
15. Sella A Sella T Peer A Berger R Frank SJ et al. Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer. J Clin Oncol 31 2013 (suppl; abstract e16023
16. Schrader AJ Boegemann M Ohlmann CH Schnoeller TJ Krabbe LM et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014; 65: 30-6
17. Scher HI Beer TM Higano CS Anand A Taplin ME et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: Phase 1-2 study. Lancet 2010; 375: 1437-46
18. Bianchini D Lorente D Rodriguez-Vida A Omlin A Pezaro C et al. Antitumour activity of enzalutamide (MDV3100) in patientswith metastatic castration-resistant prostate cancer (CRPC) pre-Treated with docetaxel and abiraterone. Eur J Cancer 2014; 50: 78-84
19. Bournakis E Gyftaki R Kafantari E Razis E Rigakos G et al. Enzalutamide (ENZA) in heavily pretreated patients with bone metastatic Castration Resistant Prostate Cancer (mCRPC) resistant to Androgen Biosynthesis Inhibitor (ABI) Treatment. The Hellenic experience of the Name Patient Access Program (NPAP). Eur Cancer Congr 2013 abstract 2906
20. Loriot Y Bianchini D Ileana E Sandhu S Patrikidou A et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013; 24: 1807-12
21. Noonan KL North S Bitting RL Armstrong AJ Ellard SL et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013; 24: 1802-7
22. Reid AH Attard G Danila DC Oommen NB Olmos D et al. Significant and sustained antitumor activity in post-docetaxel castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-95
23. Sartor O Coleman RE Nilsson S Vogelzang N Cross A et al. Safety of cytotoxic chemotherapy following radium-223 chloride (RA-223) in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) with bone metastases. ESMO 2012 abstract 2623
24. Li Y Chan SC Brand LJ Hwang TH Silverstein KA et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013; 73: 483-9
25. Mostaghel EA Marck BT Plymate SR Vessella RL Balk S et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17: 5913-25
26. van Soest RJ van Royen ME de Morreé. ES Moll JM Teubel W et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49: 3821-30
27. Egan A Dong Y Zhang H Qi Y Balk SP Sartor O. Castration-resistant prostate cancer: Daptive responses in the androgen axis. Cancer Treat Rev 2014; 40: 426-33
28. Ryan CJ Shah S Efstathiou E Smith MR Taplin ME et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011; 17: 4854-61.